Advertisement
Advertisement
QGEN
QIAGEN N.V.
51.02
USDSponsored
-0.21
-0.42%
Feb 06, 16:00 UTC -5
Closed
After-Market
50.96
-0.05
-0.11%
QGEN Earnings Reports
Positive Surprise Ratio
QGEN beat 31 of 40 last estimates.
78%
Next Report
Date of Next Report
May 05, 2026
Estimate for Q1 26 (Revenue/ EPS)
$519.55M
/$0.58
Implied change from Q4 25 (Revenue/ EPS)
-3.86%
/-6.45%
Implied change from Q1 25 (Revenue/ EPS)
+7.47%
/+1.75%
QIAGEN N.V. earnings per share and revenue
On Feb 04, 2026, QGEN reported earnings of 0.62 USD per share (EPS) for Q4 25, missing the estimate of 0.64 USD, resulting in a -3.32% surprise. Revenue reached 540.42 million, compared to an expected 541.10 million, with a -0.13% difference. The market reacted with a -0.93% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 12 analysts forecast an EPS of 0.58 USD, with revenue projected to reach 519.55 million USD, implying an decrease of -6.45% EPS, and decrease of -3.86% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
Adaptive Biotechnologies Corporation Common Stock
Report Date
Feb 05, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.09
Surprise
+51.33%
AYTU BioPharma, Inc. Common Stock
Report Date
Feb 03, 2026 For Q2 26
Estimate
-$0.61
Actual
-$1.05
Surprise
-71.57%
FAQ
What were QIAGEN N.V.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, QIAGEN N.V. reported EPS of $0.62, missing estimates by -3.32%, and revenue of $540.42M, -0.13% below expectations.
How did the market react to QIAGEN N.V.'s Q4 2025 earnings?
The stock price moved down -0.93%, changed from $51.71 before the earnings release to $51.23 the day after.
When is QIAGEN N.V. expected to report next?
The next earning report is scheduled for May 05, 2026.
What are the forecasts for QIAGEN N.V.'s next earnings report?
Based on 12
analysts, QIAGEN N.V. is expected to report EPS of $0.58 and revenue of $519.55M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement